Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | NA |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Gefitinib | |
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, in vitro knockdown, RIP, etc. |
| Sample | human NSCLC cell lines HCC827 and HCC4006 |
| Expression Pattern | up-regulated |
| Function Description | RT qPCR assays indicated that H19 was increased in gefitinib-resistant cells when compared to sensitive parent cells. Functional experiments revealed that silencing of H19 potently promoted gefitinib induced cell cytotoxicity. H19 was secreted by packaging into exosomes and this packaging process was specifically mediated by hnRNPA2B1. H19 wrapped in exosomes could be transferred to non-resistant cells, thus inducing gefitinib resistance. Moreover, treatment sensitive cells with exosomes highly expressing H19 induced gefitinib resistance, while knockdown of H19 abrogated this effect. In conclusion, H19 promoted gefitinib resistance of NSCLC cells by packaging into exosomes. |
| Pubmed ID | 30542738 |
| Year | 2018 |
| Title | Tumor-released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non-small cell lung cancer |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |